新型生物制剂在狼疮性肾炎中的应用进展

Application Progress of New Biological Agents in Lupus Nephritis

狼疮性肾炎(LN)是系统性红斑狼疮(SLE)累及肾脏导致的一种常见的继发性免疫性肾小球肾炎,其治疗原则在于延缓SLE疾病本身及并发症进展,防止终末期肾病的发生。现阶段LN的治疗方案仍以糖皮质激素、免疫抑制剂等药物为主,但存在复发率高、靶向性差、感染率高等诸多问题。而针对B淋巴细胞和T淋巴细胞等不同靶点的新型生物制剂应用于临床治疗后,极大程度上减少了激素的用量及上述药物引起的不良反应,对于改善患者的临床症状和提高生活质量具有重要意义。未来可对这一领域进行深入探索,以为LN的治疗提供新思路。

Lupus nephritis(LN)is a common secondary immune glomerulonephritis caused by systemic lupus erythematosus(SLE)in which the kidneys were involved.The treatment principle is to delay the progression of SLE disease itself and its complications,and prevent the occurrence of end-stage renal diseases.At present,the treatment protocol for LN is still mainly based on drugs such as glucocorticoids and immunosuppressants,which have many problems such as high recurrence rate,poor targeting,and high infection rate.The application of new biological agents targeting at B lymphocytes or T lymphocytes in clinical treatment greatly reduces the dosage of glucocorticoids and the adverse effects caused by the aforementioned drugs,which is of great significance in improving the patients′clinical symptoms and improving quality of life.In the future,in-depth exploration can be conducted in this field to provide new ideas for the treatment of LN.